Immunic inc koers & forum

https://www.proactiveinvestors.com/companies/news/1018051/immunic-has-a-blockbuster-clinical-pipeline-to-treat-multiple-sclerosis-and-gastrointestinal-diseases-1018051.html?rel=scroll

Een bedrijf met een grote toekomst en hoog opwaarts potentieel.

https://finance.yahoo.com/news/2-strong-buy-penny-stocks-135603450.html

Immunic, Inc. (IMUX)

We’ll start with Immunic, a clinical-stage biopharmaceutical firm at the forefront of developing orally administered small-molecule immunotherapies for chronic inflammatory and autoimmune diseases. Immunic’s work focuses on orally dosed medications, which is an important consideration. Many new drug treatments for autoimmune diseases require intravenous administration, with all the discomfort and inconvenience that entails for the patient. An orally dosed treatment avoids these difficulties.


ADVERTISEMENT

The company’s current pipeline includes several drug candidates, two in the clinic and one in pre-clinical testing, targeting multiple sclerosis, ulcerative colitis, and celiac disease. The company’s leading program targets multiple sclerosis, and is at Phase 3 in clinical trials.

On the clinical side, Immunic’s leading program is IMU-838, vidofludimus calcium, which is being tested as a treatment for both relapsing and progressive multiple sclerosis, and moderate-to-severe ulcerative colitis. The first of these tracks, on relapsing MS, is the most advanced, in a Phase 3 clinical trial. Earlier Phase 2 trials of this drug candidate showed clinically significant therapeutic activity in the treatment of MS. In April of this year, the company also announced positive Phase 2b data on the use of IMU-838 in the treatment of ulcerative colitis.

The company’s second leading pipeline program is IMU-856, under investigation as a treatment for celiac disease. This drug candidate has been exceeding the company’s expectations, showing success in proof-of-concept trials and in early-stage clinical testing. The company is preparing a Phase 2b trial of IMU-856 in patients with ongoing active celiac disease.

Based on the potential of the company’s drug candidates, and its $1.44 share price, Piper Sandler analyst Yasmeen Rahimi thinks that now is the time to get in on the action.

“We continue to believe that IMUX is an undervalued stock as we head into two key events on the horizon across two strong assets: 1) IMU-838 in ~225 PMS patients on track to read out key biomarker MFL and GFAP data in 2H23, and 2) initiation of a Ph2b celiac disease study with IMU-856 following the positive topline results from the Ph1b part C, where mgmt’s next steps will involve working diligently on the protocol and design to as quickly as possible submit an IND filing in the US to start regulatory discussions. Altogether, we continue to have high conviction for the success across the IMUX pipeline,” the analyst opined.

To this end, Rahimi rates IMUX an Overweight (i.e. Buy) and her price target, set at $28, implies an impressive upside of 1,844% over the next 12 months. (To watch Rahimi’s track record, click here)

So, that’s Piper Sandler’s view, how does the rest of the Street see the next 12 months panning out for IMUX? Based on 3 Buy ratings and 1 Hold, the analyst consensus rates the stock a Strong Buy. The $13.25 average price target indicates shares could skyrocket 820% in the next year. (See IMUX stock forecast)